Phase II Study of the Safety, Efficacy, and Immune Response of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of pembrolizumab, tadalafil, ipilimumab, and CRS-207 in patients with metastatic pancreatic adenocarcinoma who have progressed after at least one prior chemotherapy regimen.
General Information
NCT#: NCT05014776
Study ID: J2180
Trial Phase: Phase II
Trial Sponsor: Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Ipilimumab, Tadalafil, CRS-207, Pembrolizumab